Factors Associated with Death among COVID-19 Patients, Tak Province
Keywords:
COVID-19 patients, death, chronic diseases, vaccinationAbstract
The outbreak of the coronavirus 2019 disease (COVID-19) is the cause of pneumonia and death that affected the population globally. This retrospective analytical study aimed to study factors associated with death among patients with COVID-19 infection in Tak province. Data were collected from patients, s data center of the Tak Provincial Public Health Office during 1 June to 31 December 2021. The total of 15,442 cases were divided into two groups: the case study group of 258 people and the control group of 774 people through stratified random sampling. The data were analyzed by using multiple logistic regression. The results showed the factors that had a statistically significant association with death were: aged 65 years or older (ORadj = 10.00, 95%CI: 6.48-15.42, p<0.05); Burmese and stateless ethnicity (ORadj= 2.49, 95%CI: 1.56-3.98, p<0.05); chronic kidney disease (ORadj = 7.08, 95%CI: 2.02-24.81, p=0.002); having 1 chronic disease (ORadj= 3.77, 95%CI: 2.09-6.78, p<0.05); more than 1 chronic disease (ORadj = 7.26, 95%CI: 3.85-13.68, p<0.05); and dyspnea (ORadj = 6.77, 95%CI: 3.82-11.98, p<0.05). As for vaccination, it could reduce mortality from the COVID-19 disease: patients having 1 dose of the vaccine (ORadj = 0.11, 95%CI: 0.04-0.27, p<0.05), and having 2 doses (ORadj = 0.07, 95%CI: 0.02-0.27, p<0.05). In conclusion, the factors associated with the death were age 65 years and over, Burmese and statelessness ethnicity, chronic kidney disease, the number of concurrent chronic diseases, and dyspnea symptom. Moreover, vaccination could significantly reduce the risk of death of the patients. Therefore, the program design should focus on vaccination to cover such risk groups.
Downloads
References
World Health Organization. Novel coronavirus (2019- nCoV) situation report-1 [Internet]. 2020 [cited 2022 Mar 26]. Available from: https://apps.who.int/iris/ bitstream/handle/10665/330760/nCoVsitrep21Jan2020eng.pdf?sequence=3&isAllowed=y
World Health Organization. Novel coronavirus – China. [Internet]. 2020 [cited 2022 Mar 26]. Available from:https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON233
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727-33.
World Health Organization. Coronavirus disease (COVID-19) [Internet]. 2020 [cited 2022 Mar 26]. Available from: https://www.who.int/health-topics/ coronavirus
World Health Organization. Coronavirus disease 2019 (COVID-19): situation report, 76 [Internet]. 2020 [cited 2022 Mar 26]. Available from: https://apps.who. int/iris/bitstream/handle/10665/331689/nCoVsitrep05Apr2020-eng.pdf?
World Health Organization. Weekly epidemiological update -10 November 2020 [Internet]. 2020 [cited2022 Mar 30]. Available from: https://www.who.int/ publications/m/item/weekly-epidemiological-update---10-november-2020
กรมควบคุมโรค. สถานการณ์โรคไวรัสโคโรนา 2019 [อินเทอร์เน็ต]. 2563 [สืบค้นเมื่อ 22 ม.ค. 2565]. แหล่ง ข้อมูล: https://ddc.moph.go.th/viralpneumonia/eng/ file/situation/situation-no344-141263.pdf
กรมควบคุมโรค. สถานการณ์โรคไวรัสโคโรนา 2019 [อินเทอร์เน็ต]. 2564 [สืบค้นเมื่อ 22 ม.ค. 2565]. แหล่ง ข้อมูล: https://ddc.moph.go.th/viralpneumonia/eng/ file/situation/situation-no416-280264.pdf
กรมควบคุมโรค. สถานการณ์โรคไวรัสโคโรนา 2019. [อินเทอร์เน็ต]. 2564 [สืบค้นเมื่อ 22 ม.ค. 2565]. แหล่ง ข้อมูล: https://ddc.moph.go.th/viralpneumonia/eng/ file/situation/situation-no720-311264.pdf
กรมควบคุมโรค. สถานการณ์โรคไวรัสโคโรนา 2019. [อินเทอร์เน็ต]. 2564 [สืบค้นเมื่อ 22 ม.ค. 2565]. แหล่ง ข้อมูล: https://ddc.moph.go.th/viralpneumonia/eng/ file/situation/situation-no544-060764.pdf
กรมควบคุมโรค. สถานการณ์ผู้ป่วย COVID-19 [อินเทอร์เน็ต]. 2564 [สืบค้นเมื่อ 22 ม.ค. 2565]. แหล่งข้อมูล: https://ddc.moph.go.th/covid19-dashboard/?dashboard=province
Yu C, Lei Q, Li W, Wang X, Liu W, Fan X, et al. Clinical characteristics, associated factors, and predicting COVID-19 mortality risk: A retrospective study in Wuhan, China. Am J Prev Med 2020;59(2):168-75.
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180(7):934-43.
Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients withcoronavirus disease 2019: retrospective study. BMJ 2020;368:1-12.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62.
Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020; 146(1):110-8.
Ciceri F, Castagna A, Rovere-Querini P, Cobelli FD, Ruggeri A, Galli L, et al. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol 2020;217:1-8.
Portoles J, Marques M, Lopez-Sanchez P, Valdenebro MD, Munez E, Serrano ML, et al. Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak. Nephrol Dial Transplant 2020;35(8):1353-61.
Ng WH, Tipih T, Makoah NA, Vermeulen JG, Goedhals D, Sempa JB, et al. Comorbidities in SARS-CoV-2 patients: a systematic review and meta-analysis. Clin Epidemiol 2021;12(1):1-12.
Twigg III HL, Khan SH, Perkins AJ, Roberts S, Sears C, Rahman O, et al. Mortality rates in a diverse cohort of mechanically ventilated patients with novel coronavirus in the urban midwest. Crit Care Expl 2020;2(8):1- 6.
Tanriover MD, Doganay HL, Akova M, Guner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021;398(10296):213-22.
Palacios R, Batista AP, Albuquerque CSN, Patino EG, Santos JP, Conde MTRP, et al. Efficacy and safety of aCOVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study. SSRN Journal 2021;in press.
Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S, Sofiatin Y, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: an interim analysis in Indonesia. Vaccine 2021;39(44):6520- 8.
Kalligeros M, Shehadeh F, Mylona EK, Kaczynski M, Kalagara S, Atalla E, et al. Clinical outcomes of adult patients hospitalized with COVID-19 after vaccination. Trop Med Infect Dis 2021;6(4):1-6.
Amit S, Regev-Yochay G, Afek A, Kreiss, Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet 2021;397(10277):875-7.
Muthukrishnan J, Vardhan V, Mangalesh S, Koley M, Shankar S, Yadav AK, et al. Vaccination status and COVID-19 related mortality: a hospital based cross sectional study. Med J Armed Forces India 2021;77:279- 82.
Schlesselman JJ. Case-control studies: design, conduct, analysis. New York: Oxford University Press; 1982.
Goronzy JJ, Fang F, Cavanagh MM, Qi Q, Weyand CM. Naive T cell maintenance and function in human aging. J Immunol 2015;194(9):4073-80.
Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, et al. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol 2018; 8(1960):1-13.
Franceschi C, Salvioli S, Garagnani P, de Eguileor M, Monti D, Capri M. Immunobiography and the heteroge-neity of immune responses in the elderly: a focus on inflammaging and trained immunity. Front Immunol 2017;8(982):1-11.
Mueller AL, McNamara MS, Sinclair DA. 2020. Why does COVID-19 disproportionately affect older people? Aging 2020;12(10):9959-81.
United Nations Network on Migration. Impact of Covid-19 on migrants in Thailand situation report. September 2021 [Internet]. 2021 [cited 2022 Mar 26]. Available from: https://thailand.iom.int/sites/g/files/tmzbdl1371/ files/documents/UNMNW%20COVID19%20SitRep_ September.pdf
Mansouri L, Sendic S, Havervall S, Thalin C, Jacobson SH, Lundahl J. Role of kidney function and concentrations of BAFF, sPD-L1 and sCD25 on mortality in hospitalized patients with COVID-19. BMC Nephrol 2022; 23(299):1-13.
Cheng S, Zhao Y, Wang F, Chen Y, Kaminga AC, Kaminga AC, et al. Comorbidities’ potential impacts on severe and non-severe patients with COVID-19. J Med 2021;100(12):1-13.
Guan W-j, Liang W-h, Zhao Y, Liang H, Chen Z, Li-r Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55(5):1-14.
Vacharathit V, Aiewsakun P, Manopwisedjaroenet S, Srisaowakarn C, Laopanupong T, Ludowyke N, et al. CoronaVac induces lower neutralising activity against variants of concern than natural infection. Lancet Infect Dis 2021;21(10):1352-4.
กรมควบคุมโรค. แนวทางการให้วัคซีนโควิด 19 ใน สถานการณ์การระบาด ปี 2564 ของประเทศไทย. ฉบับปรับปรุง ครั้งที่ 2. สมุทรปราการ: ทีเอสอินเทอร์พริ้นท์; 2564.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
